Empagliflozin-d4 contains four deuterium atoms and is intended for use as an internal standard for the quantification of empagliflozin by GC- or LC-MS. Empagliflozin is a potent SGLT2 inhibitor (IC50 = 3.1 nM) that demonstrates a high degree of selectivity (>2,500-fold) over SGLT1, 4, 5, and 6.1 In clinical trials of patients with type 2 diabetes, formulations containing empagliflozin lowered fasting and postprandial glucose levels by increasing total glucose excretion, improving β-cell function, and shifting substrate utilization from glucose to lipids.2
1.Grempler, R., Thomas, L., Eckhardt, M., et al.Empagliflozin, a novel selective sodium glucose contransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitorsDiabetes Obes. Metab.14(1)83-90(2012) 2.Ndefo, U.A., Anidiobi, N.O., Basheer, E., et al.Empagliflozin (Jardiance): A novel SGLT2 inhibitor for the treatment of type-2 diabetesP.T.40(6)364-368(2015)